Organogenesis (ORGO) Competitors $4.35 +0.30 (+7.41%) Closing price 03:40 PM EasternExtended Trading$4.20 -0.15 (-3.33%) As of 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ORGO vs. ADPT, IMCR, SPRY, EWTX, SDGR, BHVN, ETNB, ANIP, JANX, and EVOShould you be buying Organogenesis stock or one of its competitors? The main competitors of Organogenesis include Adaptive Biotechnologies (ADPT), Immunocore (IMCR), ARS Pharmaceuticals (SPRY), Edgewise Therapeutics (EWTX), Schrodinger (SDGR), Biohaven (BHVN), 89BIO (ETNB), ANI Pharmaceuticals (ANIP), Janux Therapeutics (JANX), and Evotec (EVO). These companies are all part of the "pharmaceutical products" industry. Organogenesis vs. Its Competitors Adaptive Biotechnologies Immunocore ARS Pharmaceuticals Edgewise Therapeutics Schrodinger Biohaven 89BIO ANI Pharmaceuticals Janux Therapeutics Evotec Organogenesis (NASDAQ:ORGO) and Adaptive Biotechnologies (NASDAQ:ADPT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, dividends, valuation and analyst recommendations. Do institutionals and insiders believe in ORGO or ADPT? 49.6% of Organogenesis shares are owned by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 33.0% of Organogenesis shares are owned by company insiders. Comparatively, 6.4% of Adaptive Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts prefer ORGO or ADPT? Organogenesis currently has a consensus price target of $6.00, indicating a potential upside of 37.93%. Adaptive Biotechnologies has a consensus price target of $10.57, indicating a potential downside of 11.73%. Given Organogenesis' higher possible upside, research analysts clearly believe Organogenesis is more favorable than Adaptive Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organogenesis 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Adaptive Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Which has preferable valuation & earnings, ORGO or ADPT? Organogenesis has higher revenue and earnings than Adaptive Biotechnologies. Organogenesis is trading at a lower price-to-earnings ratio than Adaptive Biotechnologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrganogenesis$482.04M1.14$860K-$0.17-25.59Adaptive Biotechnologies$178.96M10.17-$159.49M-$0.96-12.48 Is ORGO or ADPT more profitable? Organogenesis has a net margin of -3.46% compared to Adaptive Biotechnologies' net margin of -74.84%. Organogenesis' return on equity of -4.00% beat Adaptive Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Organogenesis-3.46% -4.00% -2.26% Adaptive Biotechnologies -74.84%-62.79%-24.55% Does the media refer more to ORGO or ADPT? In the previous week, Adaptive Biotechnologies had 6 more articles in the media than Organogenesis. MarketBeat recorded 7 mentions for Adaptive Biotechnologies and 1 mentions for Organogenesis. Adaptive Biotechnologies' average media sentiment score of 0.53 beat Organogenesis' score of 0.00 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organogenesis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Adaptive Biotechnologies 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, ORGO or ADPT? Organogenesis has a beta of 1.7, indicating that its share price is 70% more volatile than the S&P 500. Comparatively, Adaptive Biotechnologies has a beta of 1.83, indicating that its share price is 83% more volatile than the S&P 500. SummaryOrganogenesis and Adaptive Biotechnologies tied by winning 8 of the 16 factors compared between the two stocks. Get Organogenesis News Delivered to You Automatically Sign up to receive the latest news and ratings for ORGO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORGO vs. The Competition Export to ExcelMetricOrganogenesisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$551.80M$2.42B$5.49B$9.01BDividend YieldN/A1.77%5.39%4.09%P/E Ratio-25.598.9827.4320.06Price / Sales1.14476.11398.25108.31Price / Cash18.11151.5836.1356.90Price / Book2.084.638.085.67Net Income$860K$31.34M$3.16B$248.47M7 Day Performance20.50%0.84%2.12%2.90%1 Month Performance54.80%7.92%4.43%5.75%1 Year Performance55.91%1.87%35.62%21.36% Organogenesis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORGOOrganogenesis4.0982 of 5 stars$4.35+7.4%$6.00+37.9%+52.3%$551.80M$482.04M-25.59950ADPTAdaptive Biotechnologies3.4608 of 5 stars$10.56+1.7%$10.57+0.1%+240.7%$1.58B$178.96M-11.00790News CoverageGap UpIMCRImmunocore2.4963 of 5 stars$31.12-0.7%$58.89+89.2%-5.9%$1.57B$310.20M-72.37320SPRYARS Pharmaceuticals3.1097 of 5 stars$16.57+4.9%$31.00+87.1%+93.4%$1.55B$89.15M-103.5690Positive NewsInsider TradeEWTXEdgewise Therapeutics2.7238 of 5 stars$14.18-0.8%$39.78+180.5%-29.2%$1.50BN/A-9.1560News CoverageAnalyst ForecastAnalyst RevisionSDGRSchrodinger2.8356 of 5 stars$20.35-0.5%$32.80+61.2%+3.1%$1.50B$207.54M-7.74790News CoverageAnalyst ForecastBHVNBiohaven3.4193 of 5 stars$14.44-0.2%$58.46+305.0%-56.8%$1.48BN/A-1.54239ETNB89BIO1.9351 of 5 stars$10.00-0.8%$26.43+164.3%+32.9%$1.47BN/A-2.9640ANIPANI Pharmaceuticals3.7253 of 5 stars$66.03+0.7%$80.13+21.3%+4.1%$1.42B$614.38M-51.99600JANXJanux Therapeutics1.7978 of 5 stars$22.88-3.1%$95.25+316.3%-38.8%$1.40B$10.59M0.0030EVOEvotec1.7251 of 5 stars$3.81+1.3%$5.93+55.7%-12.3%$1.34B$862.40M0.004,827Positive News Related Companies and Tools Related Companies Adaptive Biotechnologies Alternatives Immunocore Alternatives ARS Pharmaceuticals Alternatives Edgewise Therapeutics Alternatives Schrodinger Alternatives Biohaven Alternatives 89BIO Alternatives ANI Pharmaceuticals Alternatives Janux Therapeutics Alternatives Evotec Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORGO) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organogenesis Please log in to your account or sign up in order to add this asset to your watchlist. Share Organogenesis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ORGO Stock Alerts